<DOC>
	<DOCNO>NCT00700622</DOCNO>
	<brief_summary>The objective study demonstrate TI® Inhalation Powder combine Lantus® effective Humalog® combine Lantus® HbA1c .</brief_summary>
	<brief_title>Safety Efficacy Technosphere® Insulin Inhalation Powder Lantus® Compared Humalog® Lantus® Over 16-Weeks</brief_title>
	<detailed_description />
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Men woman ≥ 18 ≤ 80 year old Clinical diagnosis type 1 diabetes mellitus 12 month Body mass index ( BMI ) ≤ 30 kg/m2 Stable antidiabetic regimen sc insulin therapy total daily dose ≤ 1.5 IU/kg/day HbA1c &gt; 7.0 % ≤ 9.0 % Cpeptide level ≤ 0.30 pmol/mL Nonsmokers ( include cigarette , cigar , pipe , chew tobacco ) least precede 6 month Negative urine cotinine define ≤ 100 ng/mL Pulmonary function test ( PFTs ) : Forced expiratory volume 1 second ( FEV1 ) ≥ 70 % Third National Health Nutrition Examination Survey ( NHANES III ) predict FEV1 percentage FEV1/forced vital capacity ( FVC ) ≥ 70 % ( NHANES III ) predict Total lung capacity ( TLC ) ≥ 80 % predict ( Intermountain Thoracic Society [ ITS ] ) Single breath carbon monoxide diffuse capacity lung , hemoglobincorrected ( DLcoHb ) ( uncorrected ) ≥ 70 % predict For subset subject Doppler echocardiogram : right ventricular systolic pressure ( RVSP ) ≤ 40 mm Hg Visit 1 Written informed consent Treatment type antidiabetic drug , sc insulin , within precede 12 week Two severe hypoglycemic episode within 6 month screen episode severe hypoglycemia Visit 1 Visit 5 Any hospitalization emergency room visit due poor diabetic control within 6 month Visit 1 , hospitalization emergency room visit due poor diabetic control Visit 1 Visit 5 Severe complication diabetes , opinion PI , include symptomatic autonomic neuropathy ; disable peripheral neuropathy ; active proliferative retinopathy ; nephropathy renal failure , renal transplant , dialysis ; history foot ulcer ; nontraumatic amputation due gangrene ; vascular claudication Previous exposure inhale insulin product within 3 month Visit 1 History insulin pump use within 6 week Visit 1 Allergy know hypersensitivity insulin drug use trial , history hypersensitivity TI Inhalation Powder drug similar chemical structure Significant improvement pre postbronchodilator spirometry Visit 1 ( defined increase 12 % 200 mL either FEV1 FVC ) History chronic obstructive pulmonary disease ( COPD ) , clinically proven asthma , clinically important pulmonary disease ( eg , obstructive sleep apnea ) confirm pulmonary function test radiologic finding Inability perform spirometry maneuver meet recommended American Thoracic Society ( ATS ) standard acceptability repeatability criterion Active respiratory infection ( subject could return 30 day resolution rescreening ) ; respiratory infection manifest Visit 1 Visit 1 PFTs , subject schedule PFTs 30 day resolution respiratory infection . An additional hemoglobin require Major organ system disease , include : Seizure disorder Significant cardiovascular dysfunction history within 3 month Visit 1 , eg , congestive heart failure ( New York Heart Association [ NYHA ] Class III IV ) , serious arrhythmia , myocardial infarction , cardiac surgery , recurrent syncope , transient ischemic attack , cerebrovascular accident Uncontrolled hypertension systolic blood pressure &gt; 180 mm Hg diastolic blood pressure &gt; 110 mm Hg Visit 1 despite pharmacologic treatment Nephrotic syndrome ; renal dysfunction disease ; serum creatinine &gt; 2.0 mg/dL ( 0.11 mmol/L ) men &gt; 1.8 mg/dL ( 0.1 mmol/L ) woman ; blood urea nitrogen ( BUN ) &gt; 50 mg/dL ( 2.8 mmol/L ) Cancer ( excise cutaneous basal cell carcinoma ) within past 5 year history lung neoplasms History active viral cirrhotic hepatic disease abnormal liver enzyme evidence serum aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≥ 3 time upper limit normal ( ULN ) Active infection ( eg , human immunodeficiency virus [ HIV ] , hepatitis ) history severe infection within 30 day Visit 1 Anemia ( hemoglobin ≤ 10.5 g/dL woman ≤ 11.5 g/dL men ) Diagnosis systemic autoimmune collagen vascular disease require previous current treatment systemic corticosteroid , cytotoxic drug , penicillamine Any concurrent illness , diabetes mellitus , control stable therapeutic regimen Current previous chemotherapy radiation therapy might result pulmonary toxicity Use medication prescribe weight loss ( eg , sibutramine , orlistat ) within 12 week Visit 1 Any history current use amiodarone Clinically significant abnormality screen laboratory evaluation ( unless discuss approve medical monitor ) Women pregnant , lactating , plan become pregnant trial Women childbearing potential ( define premenopausal surgically sterilize postmenopausal few 2 year ) practice adequate birth control . Adequate birth control define use oral , percutaneous , transdermal contraceptive ; condom diaphragms ( double barrier ) spermicide ; intrauterine device . Postmenopausal trial include amenorrhea 2 year surgically sterile Current drug alcohol abuse history drug alcohol abuse , opinion PI , would make subject unsuitable candidate participation trial Exposure investigational medication device within 30 day trial entry , participation another clinical trial participate trial Unable unlikely comprehend follow trial protocol ( include SBGM diabetes education ) Unable unlikely comprehend use MedTone Inhaler inability use device Unable unlikely follow meal plan include least 2 meals/day ( without third meal additional snack ) Noncompliance medication procedure , PI 's opinion , might affect trial data subject safety preclude subject participation trial Any concurrent medical major psychiatric condition , opinion PI , make subject unsuitable clinical trial could limit validity inform consent impair subject 's ability participate trial For subset subject Doppler echocardiogram : Subjects leave ventricular ejection fraction ( LVEF ) ≤ 35 % Visit 1 Subjects know history sickle cell disease Previous use Redux® ( dexfenfluramine ) Pondimin® ( fenfluramine ) History valvular heart disease , include mild great aortic insufficiency moderate great mitral insufficiency Significant cardiovascular dysfunction history within 12 month Visit 1 ( eg , congestive heart failure [ NYHA Class III IV ] ) serious arrhythmia , treatment medication control treat arrhythmia , myocardial infarction , cardiac surgery , recurrent syncope , transient ischemic attack , cerebrovascular accident History pulmonary embolism deep venous thrombosis 12 month Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>